Amoena Management Holding GmbH has secured refinancing to bolster its position as a global leader in silicone breast prostheses and postoperative care products.
Target Information
Amoena Management Holding GmbH, founded in 1975, is a leading provider of medical breast care products worldwide. Headquartered in Raubling, Bavaria, the company employs over 375 individuals globally. Amoena specializes in serving breast cancer patients who have undergone partial or complete mastectomies, offering the broadest portfolio of medically certified products available in the market, including silicone breast prostheses and postoperative care products. Recently, they have expanded their offerings to include lymph products for breast care and a variety of medical specialty clothing.
After introducing the world's first silicone-filled breast prosthesis, Amoena has established itself as a leader in quality and innovation within the healthcare sector.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The healthcare industry in Germany is characterized by its advanced infrastructure and innovative medical technologies. With a strong emphasis on research and development, Germany remains at the forefront of healt
Similar Deals
Blue Owl Capital → ITM Isotope Technologies Munich SE
2025
European Investment Bank → Smart Reporting
2023
Verdane → Clue
2026
Apera and OLB
invested in
Amoena Management Holding GmbH
in 2025
in a Venture Debt deal